WO1999062464A1 - Topical composition for treatment of baldness - Google Patents
Topical composition for treatment of baldness Download PDFInfo
- Publication number
- WO1999062464A1 WO1999062464A1 PCT/IL1999/000274 IL9900274W WO9962464A1 WO 1999062464 A1 WO1999062464 A1 WO 1999062464A1 IL 9900274 W IL9900274 W IL 9900274W WO 9962464 A1 WO9962464 A1 WO 9962464A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- topical
- flutamide
- treatment
- finasteride
- topical composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 230000000699 topical effect Effects 0.000 title claims abstract description 25
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 14
- 230000003676 hair loss Effects 0.000 title description 4
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960002074 flutamide Drugs 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 229960004039 finasteride Drugs 0.000 claims abstract description 16
- 206010068168 androgenetic alopecia Diseases 0.000 claims abstract description 9
- 229960002653 nilutamide Drugs 0.000 claims abstract description 6
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 230000003637 steroidlike Effects 0.000 claims abstract description 4
- 235000019441 ethanol Nutrition 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000006260 foam Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 210000004761 scalp Anatomy 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 210000004209 hair Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 229960003473 androstanolone Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000004919 hair shaft Anatomy 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 108010044467 Isoenzymes Proteins 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 239000003936 androgen receptor antagonist Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- WFSMVVDJSNMRAR-UHFFFAOYSA-N 2-[2-(2-ethoxyethoxy)ethoxy]ethanol Chemical class CCOCCOCCOCCO WFSMVVDJSNMRAR-UHFFFAOYSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 241000282519 Macaca speciosa Species 0.000 description 1
- 229920003100 Methocel™ E15 LV Polymers 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003806 hair structure Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003956 nonsteroidal anti androgen Substances 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940072254 proscar Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- -1 stick Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Definitions
- the present invention relates to a topical composition for treatment and prevention of male-pattern baldness.
- the new formulations are preferably applied as gels, cream, spray or washable ointments, providing an effective, compliant, and easy mode of delivery of the agents onto and into the scalp area.
- the pathogenesis of androgenetic alopecia involves increased scalp follicle susceptibility to androgens.
- Scalp follicles in this alopecia contain increased levels and activity of 5a-reductase, which converts testosterone (T) to dihydrotestosterone (DHT).
- DHT shortens the hair cycle and progressively miniaturizes scalp follicles. The miniaturized follicles all remain present and thus the possibility of reversal by re-enlargement exists.
- other hair sites are testosterone independent in general, although at puberty, DHT causes hypertrophy in follicles of the beard and mustache.
- the nonsteroidal anti-androgen flutamide is produced by Schering-Plough and has been introduced as a new potent compound tested clinically for treatment of prostatic carcinoma. So far, flutamide has not been introduced to any clinical study for testing its efficacy in male-pattern baldness. It is not known if it is effective systemically (as finasteride), or topically.
- a third isoenzyme of 5a-reductase is Nilutamide, which is a non-steroidal androgen antagonist with anti-androgenic properties similar to those of flutamide.
- Anandron which is manufactured by Roussel (U.S. pat. 4,097,578).
- a topical composition for treatment and/or prevention of male-pattern baldness comprising between about 0.5-10 wt.% of an active ingredient selected from the group consisting of finasteride, flutamide, nilutamide and mixtures thereof, in combination with a pharmaceutically acceptable topical carrier, said topical carrier comprising between 10-80 wt.% alcohol and said composition being devoid of sex-related steroidal active ingredients.
- said active ingredient is present in an amount of between about 1 and 10 wt.%.
- the active ingredients are incorporated into pharmaceutically accepted topical dosage forms such as gels, creams, ointments, solutions, sprays, foams, or 'roll-on' preparations.
- the resulting formulations are applied 1-6 times daily to the scalp skin of male-pattern bald persons.
- the preparations can be applied on the skin using tubes (gel, cream etc.), pressure vessels (spray, aerosol, foam), bottles, containers (e.g., shampoo), pad, stick, or 'roll-on' applicators (gel, solutions).
- the pH of dosage forms will be between 5-8 and may contain polyhydroxy compounds such as propylene glycol, glycerine, polyethylene glycols and so on.
- a preferred formulation could be one that contains ethyl alcohol at concentrations from 10% to 70% by weight. Such formulations could form a film over the skin, thus penetrating the active ingredient in a more controllable manner for a longer time.
- the rationale behind using these active ingredients in a topical formulation is to reduce the systemic exposure of these drugs during their chronic use, and to increase the local efficacy on scalp follicles, especially with finasteride which is known to have less affinity to scalp 5a-reductase.
- the present invention therefore, provides topical compositions comprising finasteride, flutamide, nilutamide or mixtures thereof, which can successfully remit androgen-related baldness.
- compositions and methods for inhibiting the action of androgens as wel as methods for treatment of male-pattern baldness, utilizing synergistic compositions, comprising a combination of a 5 ⁇ -reductase enzyme inhibitor and an androgen receptor blocking agent in a pharmaceutically and dermatologically acceptable vehicle.
- said patent discloses in Table I for comparative purposes a composition containing 0.05 w/v% flutamide, however specifically states in analysis of said table that ' each combination of 5 ⁇ -reductase inhibitor and androgen receptor blocker produces a synergistic effect as compared to the effects of 5 ⁇ -reductase inhibitor and androgen receptor blocker alone.”
- said patent is a teaching away from the discovery of the present invention of the superior effectiveness of the active ingredients defined herein, alone and not in combination with a sex-related steroid such as progesterone.
- example 16 is the only example incorporating 0.05 w/v% flutamide, together with 0.025 w/v% progesterone and this example does not use alcohol as a carrier and therefore also does not teach the advantage of the use of alcohol as a carrier for a composition containing flutamide or one of the other active ingredients of the present invention.
- the compositions of the present invention comprise a safe and effective amount of topically-administered, dermally-applied or potentially dermally-applied active ingredient, in combination with a pharmaceutically acceptable carrier for topical application.
- composition of this invention will comprise a pharmaceutically- or cosmetically-accepted vehicle, selected from the group consisting of oil-in-water or water-in-oil emulsions applied as a cream, lotion, ointment, stick, foam, spray or shampoo.
- vehicle is selected from the group consisting of gellified solutions, suspensions or emulsions
- gelling agent will selected from the group consisting of polysaccharides such as cellulose derivatives, acrylic polymers, proteins (e.g., gelatin), polyhydroxy compounds (e.g., polyethylene glycols 300 - 4000), and polyoxyalkylene-fatty alcohols (e.g., Emulgin B3, POE-3 cetostearyl alcohol).
- Poly- or oligo- hydroxy compounds or their derivatives can be used as cosolvents, penetration enhancers, or cosmetic adjuvants. These compounds can be selected from the group of polyalkylene glycols, poloxamers, and di- or tri- ethylene glycol ethyl ethers. Up to 60% w/w of a water-soluble, volatile 2-4C lower alkanol (and preferably is ethanol) can be used as a co-solvent or a film-forming agent, or as a peripheral vasodilator. Description of Preferred Embodiments
- Fig. 1 is a graphic representation of mean number of hair per graft after treatment with compositions according to the present invention
- Fig. 2 is a graphic representation of mean length of hair shafts after treatment with compositions according to the present invention.
- Fig. 3 is a graphic representation of mean diameter of hair shafts after treatment with compositions according to the present invention.
- mice (Charles River, UK), 2-3 months of age, were used in this study. The mice were raised in a pathogen-free animal facility.
- Skin grafting 0.5mm 2 punch grafts obtained from scalp skin of bald individuals were used for transplantation to the SCID mice. The transplantation was performed as previously described (Gilhar et al., Br. J. Dermatol., 119, 767-770, 1988). Each graft was inserted through an incision in the skin, into the subcutaneous tissue over the lateral thoracic cage of each mouse, and covered with a standard band aid dressing. The dressing was removed on day 7.
- Treatment 100 mg specimens of the topical preparation were spread gently over the transplanted graft. The application was performed twice daily. Histology: Biopsies were taken from the bald grafts before and at the end of the study. Fixation of tissue for routine histological sections was carried out in 10% neutral buffered formaldehyde solution. Horizontal sections were made of these biopsies stained with hematoxylin and eosin, and examined under light microscopy. Measurement of hair growth: The number of hairs per graft and the hair lengths were determined under X5 magnification. The hair shaft diameters were measured microscopically on the horizontal sections with the aid of a calibrated ocular micrometer. Hair structures in the histological specimens were counted.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a topical composition for treatment and/or prevention of male-pattern baldness comprising between about 0.5-10 wt.% of an active ingredient selected from the group consisting of finasteride, flutamide, nilutamide and mixtures thereof, in combination with a pharmaceutically acceptable topical carrier, said topical carrier comprising between 10-80 wt.% alcohol and said composition being devoid of sex-related steroidal active ingredients.
Description
TOPICAL COMPOSITION FOR TREATMENT OF BALDNESS Technical Field
The present invention relates to a topical composition for treatment and prevention of male-pattern baldness. The new formulations are preferably applied as gels, cream, spray or washable ointments, providing an effective, compliant, and easy mode of delivery of the agents onto and into the scalp area. Background of the Invention
The pathogenesis of androgenetic alopecia (male-pattern baldness) involves increased scalp follicle susceptibility to androgens. Scalp follicles in this alopecia contain increased levels and activity of 5a-reductase, which converts testosterone (T) to dihydrotestosterone (DHT). DHT shortens the hair cycle and progressively miniaturizes scalp follicles. The miniaturized follicles all remain present and thus the possibility of reversal by re-enlargement exists. Unlike the scalp hair, other hair sites are testosterone independent in general, although at puberty, DHT causes hypertrophy in follicles of the beard and mustache.
Two different isoenzymes of 5a-reductase were found in humans, one in the skin of the scalp and another in the prostate where at high levels it forms benign prostatic hypertrophy. Finasteride is known to more effectively inhibit the prostate isoenzyme than the scalp 5a-reductase. Nevertheless, it decreased the level of DHT in bald scalps after a long-term oral administration. Therefore, several studies has been carried out with oral finasteride alone in humans (Dallob et al., J. Clin. Endocrinol. Metab., 79, 703-706, 1994; Gormley et al., . Clin. Endocrinol. Metab., 70, 1136-1141 , 1990) or in combination with topical minoxidil on stumptail macaque (Diani et al., . Clin. Endocrinol. Metab., 74, 345-350, 1992). Finasteride was introduced by Merck in 1989 (MK-906, Proscar®) and has demonstrated few adverse effects. Unwanted effects occur in fewer than 5% of patients and usually relate to decreased libido and impotence. Up to a 25% reduction in semen volume can be expected in some patients without any changes in sperm counts, motility, or morphologic features. The nonsteroidal anti-androgen flutamide is produced by Schering-Plough and has been introduced as a new potent compound tested clinically for treatment of prostatic carcinoma. So far, flutamide has not been introduced to any clinical study for testing its efficacy in male-pattern baldness. It is
not known if it is effective systemically (as finasteride), or topically. A third isoenzyme of 5a-reductase is Nilutamide, which is a non-steroidal androgen antagonist with anti-androgenic properties similar to those of flutamide. Like flutamide, it is used in the treatment of prostatic carcinoma in a product called Anandron which is manufactured by Roussel (U.S. pat. 4,097,578).
It has been discovered in the present invention that finasteride and, especially, flutamide in a pharmaceutically-accepted topical base, pre-designed to penetrate the agents deep into the skin, significantly increase hair growth in bald scalp skin. Disclosure of the Invention
Thus, according to the present invention there is now provided a topical composition for treatment and/or prevention of male-pattern baldness comprising between about 0.5-10 wt.% of an active ingredient selected from the group consisting of finasteride, flutamide, nilutamide and mixtures thereof, in combination with a pharmaceutically acceptable topical carrier, said topical carrier comprising between 10-80 wt.% alcohol and said composition being devoid of sex-related steroidal active ingredients.
In preferred embodiments of the present invention said active ingredient is present in an amount of between about 1 and 10 wt.%.
In the practice of this invention the active ingredients are incorporated into pharmaceutically accepted topical dosage forms such as gels, creams, ointments, solutions, sprays, foams, or 'roll-on' preparations. The resulting formulations are applied 1-6 times daily to the scalp skin of male-pattern bald persons. The preparations can be applied on the skin using tubes (gel, cream etc.), pressure vessels (spray, aerosol, foam), bottles, containers (e.g., shampoo), pad, stick, or 'roll-on' applicators (gel, solutions). The pH of dosage forms will be between 5-8 and may contain polyhydroxy compounds such as propylene glycol, glycerine, polyethylene glycols and so on. A preferred formulation could be one that contains ethyl alcohol at concentrations from 10% to 70% by weight. Such formulations could form a film over the skin, thus penetrating the active ingredient in a more controllable manner for a longer time.
Detailed Description of the Invention
The rationale behind using these active ingredients in a topical formulation is to reduce the systemic exposure of these drugs during their chronic use, and to increase the local efficacy on scalp follicles, especially with finasteride which is known to have less affinity to scalp 5a-reductase. The present invention, therefore, provides topical compositions comprising finasteride, flutamide, nilutamide or mixtures thereof, which can successfully remit androgen-related baldness.
It should be defined, that by the term "comprising" as used in the present invention is meant that various other inactive ingredients, compatible drugs and medicaments can be employed in the compositions and is used in the manner disclosed, provided that said further active ingredients are not sex-related steroids which have undesirable side effects even when administered topically.
In U.S. patents 4,684,35 and 5,053,403 there are described compositions and methods for inhibiting the action of androgens, as wel as methods for treatment of male-pattern baldness, utilizing synergistic compositions, comprising a combination of a 5α-reductase enzyme inhibitor and an androgen receptor blocking agent in a pharmaceutically and dermatologically acceptable vehicle.
Interalia said patent discloses in Table I for comparative purposes a composition containing 0.05 w/v% flutamide, however specifically states in analysis of said table that ' each combination of 5α-reductase inhibitor and androgen receptor blocker produces a synergistic effect as compared to the effects of 5α-reductase inhibitor and androgen receptor blocker alone." Thus, said patent is a teaching away from the discovery of the present invention of the superior effectiveness of the active ingredients defined herein, alone and not in combination with a sex-related steroid such as progesterone.
It is also to be noted that in US patent 5,053,403, example 16 is the only example incorporating 0.05 w/v% flutamide, together with 0.025 w/v% progesterone and this example does not use alcohol as a carrier and therefore also does not teach the advantage of the use of alcohol as a carrier for a composition containing flutamide or one of the other active ingredients of the present invention.
The compositions of the present invention comprise a safe and effective amount of topically-administered, dermally-applied or potentially dermally-applied active ingredient, in combination with a pharmaceutically acceptable carrier for topical application. Thus, the composition of this invention will comprise a pharmaceutically- or cosmetically-accepted vehicle, selected from the group consisting of oil-in-water or water-in-oil emulsions applied as a cream, lotion, ointment, stick, foam, spray or shampoo. If the vehicle is selected from the group consisting of gellified solutions, suspensions or emulsions, the gelling agent will selected from the group consisting of polysaccharides such as cellulose derivatives, acrylic polymers, proteins (e.g., gelatin), polyhydroxy compounds (e.g., polyethylene glycols 300 - 4000), and polyoxyalkylene-fatty alcohols (e.g., Emulgin B3, POE-3 cetostearyl alcohol). Poly- or oligo- hydroxy compounds or their derivatives can be used as cosolvents, penetration enhancers, or cosmetic adjuvants. These compounds can be selected from the group of polyalkylene glycols, poloxamers, and di- or tri- ethylene glycol ethyl ethers. Up to 60% w/w of a water-soluble, volatile 2-4C lower alkanol (and preferably is ethanol) can be used as a co-solvent or a film-forming agent, or as a peripheral vasodilator. Description of Preferred Embodiments
While the invention will now be described in connection with certain preferred embodiments in the following examples and with reference to the attached figures so that aspects thereof may be more fully understood and appreciated, it is not intended to limit the invention to these particular embodiments. On the contrary, it is intended to cover all alternatives, modifications and equivalents as may be included within the scope of the invention as defined by the appended claims. Thus, the following examples which include preferred embodiments will serve to illustrate the practice of this invention, it being understood that the particulars shown are by way of example and for purposes of illustrative discussion of preferred embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of formulation procedures as well as of the principles and conceptual aspects of the invention.
Brief Description of the Drawings
In the drawings:
Fig. 1 is a graphic representation of mean number of hair per graft after treatment with compositions according to the present invention;
Fig. 2 is a graphic representation of mean length of hair shafts after treatment with compositions according to the present invention; and
Fig. 3 is a graphic representation of mean diameter of hair shafts after treatment with compositions according to the present invention.
Example 1
Ingredient Percent by weight
Flutamide 1.0
Ethanol 30.0
Propylene glycol 24.0
Glycerine 3.0
Arlacel 186* 1.0
Methocel E15-LV** 4.0
Distilled water q.s.
* glyceryl mono and di- ■ oleate
** Hydroxypropyl methylcellulose
Example 2
Ingredient Percent bv weiqht
Finasteride 1.0
Ethanol 58.0
Propylene glycol 20.0
Glycerine 2.0
Arlacel 186* 1.0
EthoceMOO** 4.0
Distilled water q.s.
* glyceryl mono and di- - oleate
** Ethylcellulose
Comparative Example 3
Topical formulations of finasteride and flutamide to re-enlarge hair follicles in an animal model were tested. It was found that both inhibitors were effective (i.e., in baldness remission), when applied in a topical dermal composition. It was, however, unexpectedly found that flutamide possessed a significant beneficial property over finasteride. Experimental procedure:
Animals: SCID mice (Charles River, UK), 2-3 months of age, were used in this study. The mice were raised in a pathogen-free animal facility. Skin grafting: 0.5mm2 punch grafts obtained from scalp skin of bald individuals were used for transplantation to the SCID mice. The transplantation was performed as previously described (Gilhar et al., Br. J. Dermatol., 119, 767-770, 1988). Each graft was inserted through an incision in the skin, into the subcutaneous tissue over the lateral thoracic cage of each mouse, and covered with a standard band aid dressing. The dressing was removed on day 7.
Treatment: 100 mg specimens of the topical preparation were spread gently over the transplanted graft. The application was performed twice daily. Histology: Biopsies were taken from the bald grafts before and at the end of the study. Fixation of tissue for routine histological sections was carried out in 10% neutral buffered formaldehyde solution. Horizontal sections were made of these biopsies stained with hematoxylin and eosin, and examined under light microscopy. Measurement of hair growth: The number of hairs per graft and the hair lengths were determined under X5 magnification. The hair shaft diameters were measured microscopically on the horizontal sections with the aid of a calibrated ocular micrometer. Hair structures in the histological specimens were counted.
The enclosed Figures 1-3 and Table I present the significant differences between formulation containing Finasteride (comp.A), formulation containing flutamide (comp.B), and placebo (vehicle only, comp.C) in the mean hair per graft, mean length, mean diameter of the shafts, and structuresof the growth stages of the hair. It is shown that flutamide and finasteride have a significantly higher effect than placebo in all tested parameters, however, flutamide demonstrates
significantly more hair per graft and significantly longer hair shafts than finasteride. Both compounds have a similar effect on the diameter of the hair shafts. Table I
In Table II hereinafter it can be seen that there is no difference in the systemic levels of testosterone or dihydrotestosterone following administrations of the drugs or their vehicle, demonstrating a clearly topical effect of the dermal drug application.
Table II
Serum T/DHT Levels (in nmole/L)
It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative examples and that the present invention may be embodied in other specific forms without departing from the essential attributes thereof, and it is therefore desired that the present embodiments and examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Claims
1. A topical composition for treatment and/or prevention of male-pattern baldness comprising between about 0.5-10 wt.% of an active ingredient selected from the group consisting of finasteride, flutamide, nilutamide and mixtures thereof, in combination with a pharmaceutically acceptable topical carrier, said topical carrier comprising between 10-80 wt.% alcohol and said composition being devoid of sex-related steroidal active ingredients.
2. A topical composition according to claim 1 , comprising between about 1-10 wt.% of active ingredient therein.
3. A topical composition according to claim 1 , wherein said active ingredient is flutamide.
4. A topical composition according to claim 1 , wherein said topical carrier is selected from the group consisting of gells, creams, ointments, solutions, sprays, foams and roll-on preparations.
5. A topical composition according to claim 1 , wherein said topical carrier comprises about 10-70 wt.% ethyl alcohol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL124,764 | 1998-06-04 | ||
| IL12476498A IL124764A0 (en) | 1998-06-04 | 1998-06-04 | Topical composition for treatment of baldness |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1999062464A1 true WO1999062464A1 (en) | 1999-12-09 |
Family
ID=11071587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IL1999/000274 WO1999062464A1 (en) | 1998-06-04 | 1999-05-24 | Topical composition for treatment of baldness |
Country Status (2)
| Country | Link |
|---|---|
| IL (1) | IL124764A0 (en) |
| WO (1) | WO1999062464A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000072883A3 (en) * | 1999-06-02 | 2001-08-23 | Aviana Biopharm | Pharmaceutical transdermal compositions |
| WO2002026325A3 (en) * | 2000-09-29 | 2002-08-22 | Univ California | Restoration of perturbed barrier function by application of antiandrogens |
| WO2003055454A1 (en) * | 2001-12-21 | 2003-07-10 | Ponsus Pharma Ab | New composition |
| DE10303509A1 (en) * | 2002-08-23 | 2004-03-04 | Koc, Felix, Dr. | Hair growth promoting composition contains finasteride for oral administration in combination with biotin or for external administration |
| CN100415239C (en) * | 2005-05-16 | 2008-09-03 | 济南百诺医药科技开发有限公司 | Finasteride High Concentration Solution and Its Application |
| EP2857002A4 (en) * | 2012-05-30 | 2015-12-09 | Asahi Glass Co Ltd | COMPOSITION FOR CAPILLARY GROWTH |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985002543A1 (en) * | 1983-12-12 | 1985-06-20 | Kaszynski Edwin G | Hair growth modification |
| US4684635A (en) * | 1984-05-11 | 1987-08-04 | Norman Orentreich | Compositions and methods for inhibiting the action of androgens |
| JPS62265213A (en) * | 1986-05-12 | 1987-11-18 | Hideharu Tamaki | Hair tonic |
| US4720489A (en) * | 1984-10-15 | 1988-01-19 | Douglas Shander | Hair growth modification with ornithine decarboxylase inhibitors |
| EP0285382A2 (en) * | 1987-04-03 | 1988-10-05 | Merck & Co. Inc. | Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones |
| WO1995010284A1 (en) * | 1993-10-15 | 1995-04-20 | Merck & Co., Inc. | Method of treating androgenic alopecia with 5-alpha reductase inhibitors |
| WO1997011702A1 (en) * | 1995-09-27 | 1997-04-03 | Merck & Co., Inc. | Method of preventing androgenetic alopecia with 5-alpha reductase inhibitors |
| WO1997029735A1 (en) * | 1996-02-19 | 1997-08-21 | Monash University | Dermal penetration enhancers and drug delivery systems involving same |
-
1998
- 1998-06-04 IL IL12476498A patent/IL124764A0/en unknown
-
1999
- 1999-05-24 WO PCT/IL1999/000274 patent/WO1999062464A1/en active Application Filing
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985002543A1 (en) * | 1983-12-12 | 1985-06-20 | Kaszynski Edwin G | Hair growth modification |
| US4684635A (en) * | 1984-05-11 | 1987-08-04 | Norman Orentreich | Compositions and methods for inhibiting the action of androgens |
| US4720489A (en) * | 1984-10-15 | 1988-01-19 | Douglas Shander | Hair growth modification with ornithine decarboxylase inhibitors |
| JPS62265213A (en) * | 1986-05-12 | 1987-11-18 | Hideharu Tamaki | Hair tonic |
| EP0285382A2 (en) * | 1987-04-03 | 1988-10-05 | Merck & Co. Inc. | Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones |
| WO1995010284A1 (en) * | 1993-10-15 | 1995-04-20 | Merck & Co., Inc. | Method of treating androgenic alopecia with 5-alpha reductase inhibitors |
| WO1997011702A1 (en) * | 1995-09-27 | 1997-04-03 | Merck & Co., Inc. | Method of preventing androgenetic alopecia with 5-alpha reductase inhibitors |
| WO1997029735A1 (en) * | 1996-02-19 | 1997-08-21 | Monash University | Dermal penetration enhancers and drug delivery systems involving same |
Non-Patent Citations (1)
| Title |
|---|
| DATABASE WPI Week 198801, Derwent World Patents Index; AN 1988-002667, XP002119136, "Powerful hair tonic agent with little side effect - contains A-nor-progesterone, hydroxy-dimethyl estrenone, trifluoro-methyl-nitro-M-propynotoluidine etc." * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000072883A3 (en) * | 1999-06-02 | 2001-08-23 | Aviana Biopharm | Pharmaceutical transdermal compositions |
| WO2002026325A3 (en) * | 2000-09-29 | 2002-08-22 | Univ California | Restoration of perturbed barrier function by application of antiandrogens |
| WO2003055454A1 (en) * | 2001-12-21 | 2003-07-10 | Ponsus Pharma Ab | New composition |
| DE10303509A1 (en) * | 2002-08-23 | 2004-03-04 | Koc, Felix, Dr. | Hair growth promoting composition contains finasteride for oral administration in combination with biotin or for external administration |
| CN100415239C (en) * | 2005-05-16 | 2008-09-03 | 济南百诺医药科技开发有限公司 | Finasteride High Concentration Solution and Its Application |
| EP2857002A4 (en) * | 2012-05-30 | 2015-12-09 | Asahi Glass Co Ltd | COMPOSITION FOR CAPILLARY GROWTH |
Also Published As
| Publication number | Publication date |
|---|---|
| IL124764A0 (en) | 1999-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3710380B2 (en) | Pharmaceutical solution | |
| JP5677299B2 (en) | Film-forming liquid formulation for drug release to the hair and scalp | |
| CN109528725B (en) | Nanometer composition containing diaminopyrimidine oxide and pyrrolidinyl diaminopyrimidine oxide, and preparation method and application thereof | |
| JP2562455B2 (en) | Improved osmotic topical pharmaceutical composition | |
| US8039494B1 (en) | Compositions and methods for treating diseases of the nail | |
| KR101467568B1 (en) | Pharmaceutical solution containing minoxidil with enhanced dermal retention and hair growing effect | |
| JP2015038101A (en) | Composition and method for treating disease of nail | |
| US20230021330A1 (en) | Topical formulations of 5-alpha-reductase inhibitors and uses thereof | |
| JP2010168407A (en) | Composition and method for treating alopecia | |
| JP2002080328A (en) | Hair tonic for preventing or treating hair loss | |
| JP2001520184A (en) | Topical antifungal composition | |
| JPH06502160A (en) | Steroid derivative-containing composition | |
| Sintov et al. | New topical antiandrogenic formulations can stimulate hair growth in human bald scalp grafted onto mice | |
| US12053481B2 (en) | Compositions and methods for deep dermal drug delivery | |
| JPH08507785A (en) | Topical composition for inhibiting hair growth | |
| JP2009242397A (en) | Cosmetic composition comprising derivative of imido-percarboxylic acid and n-acylated ester of amino acid | |
| NO813931L (en) | ANTIMYCOTIC AGENT WITH HIGH EFFICIENT SUBSTANCE RELEASE IN THE FORM OF ELASTIC LIQUID PLASTERS | |
| JP3981074B2 (en) | Topical composition for hair follicle transport of ornithine decarboxylase inhibitors | |
| JP2002053438A (en) | Use of prostaglandin EP-2 and / or EP-4 receptor antagonists in cosmetic formulations to attenuate, reduce or stop the growth of head and other hair | |
| WO1999062464A1 (en) | Topical composition for treatment of baldness | |
| KR20220044739A (en) | topical composition | |
| JPH01230518A (en) | Preparation for preventing or treating baldness and alopecia | |
| LU87091A1 (en) | COMBINATION OF PYRIMIDINE DERIVATIVES AND STEROIDIAN ANTI-INFLAMMATORY AGENTS FOR INDUCING AND STIMULATING HAIR GROWTH AND REDUCING FALLING | |
| EP0028525A2 (en) | Hair treatment agent promoting the growth of hair and preventing dandruff | |
| JP4001467B2 (en) | Cosmetic for hair growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |